UCB receives CHMP positive opinion for adjunctive use of BRIVIACT ...
(WorldNews Belgium)

CHMP positive opinion for BRIVIACT® (brivaracetam) extends therapeutic indication to include adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy from 4 years of age.1 Epilepsy is the most common serious neurological disorder among children and young adults with a prevalence in Europe ranging from 3.2 - 5.1 per 1,000.2 Despite this high prevalence, approximately 10 - 29% of paediatric epilepsy patients experience inadequate seizure control with currently available anti-epileptic drugs.3,4 Brussels (Belgium), 1st June 2018 - 18:00 (CEST): UCB has today announced that the Committee for Medicinal Products for Human Use...